Dailypharm Live Search Close

The power of FDA-approved new drugs

By Chon, Seung-Hyun | translator Choi HeeYoung

22.12.06 10:57:02

°¡³ª´Ù¶ó 0
Cenobamate surpasses $100 million in exports



SK Biopharm announced on the 6th that it won the "Tower of Exporting $100 million" at the 59th Trade Day ceremony held at COEX in Gangnam-gu, Seoul on the 5th. SK Biopharm's independently developed innovative new drug, Cenobamate, surpassed $100 million in exports to the U.S. and Europe from July 1, 2021, to June 30, 2022. This is the first time that a domestic pharmaceutical company has won the top $100 million in exports with a single innovative new drug developed by itself.

Cenobamate is a new drug for epilepsy that SK Biopharm has independently carried out the entire process from initial development to FDA approval. It is prescribed for adult epilepsy patients with partial seizure symptoms. It is an

Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)